Inhaled beta2‐agonist, formoterol, enhances intense exercise performance, and sprint ability in elite cyclists

Purpose Many athletes use long‐acting beta2‐agonist formoterol in treatment of asthma. However, studies in non‐athlete cohorts demonstrate that inhaled formoterol can enhance sprint performance calling into question whether its use in competitive sports should be restricted. We investigated whether formoterol at upper recommended inhaled doses (54 μg) would enhance sprint ability and intense exercise performance in elite cyclists. Methods Twenty‐one male cyclists (V̇O2max: 70.4 ± 4.3 mL × min−1 × kg−1, mean ± SD) completed two 6‐s all‐out sprints followed by 4‐min all‐out cycling after inhaling either 54 μg formoterol or placebo. We also assessed cyclists' leg muscle mass by dual‐energy X‐ray absorptiometry and muscle fiber type distribution of vastus lateralis biopsies. Results Peak and mean power output during the 6‐s sprint was 32 W (95% CI, 19–44 W, p